文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

内皮损伤信号提示危重症患者难治性急性肾损伤

Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients.
PubMed 文献 · Shock · 2017-01-01
一句话结论在危重症急性肾损伤患者中,入院时可溶性血栓调节蛋白(sTM)最高四分位组患者恢复既往肾功能的几率显著降低(HR 0.39)。

本研究基于「降钙素原与生存研究」多中心ICU队列,纳入213例入ICU时存在急性肾损伤且无慢性肾病、存活超过24小时的患者,随访28天。以可溶性血栓调节蛋白(sTM)衡量内皮损伤,以中性粒细胞明胶酶相关脂质运载蛋白(NGAL)衡量肾脏炎症损伤。调整年龄、性别、血管活性药、机械通气及入院时肌酐、降钙素原、血小板、胆红素后,sTM最高四分位组恢复既往肾功能的几率显著低于三个较低四分位组(HR 0.39,95%CI 0.21-0.73,P=0.003),而NGAL无此预测作用(HR 1.20,95%CI 0.72-2.00,P=0.48)。降钙素原最高四分位组恢复率亦较低(HR 0.59,95%CI 0.36-0.98,P=0.04)。作者认为内皮崩解可能是难治性急性肾损伤发病的关键环节。

要点

  • 入ICU时sTM位于最高四分位的急性肾损伤患者,恢复既往肾功能的几率显著低于三个较低四分位组(HR 0.39,95%CI 0.21-0.73,P=0.003)。
  • 反映肾脏初始炎症损伤程度的NGAL未能预测肾功能恢复(最高四分位组 vs 三个较低四分位组 HR 1.20,95%CI 0.72-2.00,P=0.48)。
  • 细菌感染标志物降钙素原最高四分位组恢复率亦较低(HR 0.59,95%CI 0.36-0.98,P=0.04)。
  • 213例入ICU时急性肾损伤患者中,99例在随访期间恢复既往肾功能。
  • 作者认为内皮崩解可能是难治性急性肾损伤发病的关键环节。

适用人群与场景

  • 来自「降钙素原与生存研究」多中心ICU队列,入ICU后随访28天。
  • 纳入无慢性肾病、入ICU后存活超过24小时、且入ICU时留有血浆样本可供生物标志物分析的患者。
  • 共213例入ICU时存在急性肾损伤的患者纳入分析。

诊断标准与关键阈值

  • 急性肾损伤按「肾脏病改善全球预后」(KDIGO)指南定义。
  • 肾功能恢复定义为:存活且连续五天无需肾脏替代治疗,且肌酐水平持续低于入院前水平的1.5倍。

研究设计与关键结果

  • 研究类型为多中心ICU队列分析,样本量213例入ICU时存在急性肾损伤的患者,其中99例在随访期间恢复既往肾功能。
  • 调整年龄、性别、血管升压药治疗、机械通气及入院时肌酐、降钙素原、血小板、胆红素水平后,sTM最高四分位组 vs 三个较低四分位组恢复既往肾功能的HR 0.39(95%CI 0.21-0.73,P=0.003)。
  • NGAL最高四分位组 vs 三个较低四分位组预测肾功能恢复的HR 1.20(95%CI 0.72-2.00,P=0.48)。
  • 降钙素原最高四分位组 vs 三个较低四分位组与恢复率的HR 0.59(95%CI 0.36-0.98,P=0.04)。

证据类型、等级与局限

  • 证据类型:多中心ICU队列研究(源自「降钙素原与生存研究」队列)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为内皮崩解可能是难治性急性肾损伤发病的关键环节。
  • 原文结论指出,sTM水平高的急性肾损伤患者恢复既往肾功能的机会降低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Critically ill patients with acute kidney injury (AKI) are heterogeneous on pathophysiology and prognosis. The role of endothelial damage in the pathogenesis of refractory AKI has not been clarified. The aim was to determine if biomarkers of endothelial damage, independently of the inflammatory insult on the kidney, can predict recovery of acute kidney injury.

METHODS: From the "Procalcitonin And Survival Study" multicenter intensive care unit cohort, followed for 28 days after admission, we included patients without chronic kidney disease, who survived >24 h after admission and with plasma samples at admission available for biomarker analysis. We defined AKI by the "Kidney Disease: Improving Global Outcomes" guidelines and recovery of prior kidney function as alive for five consecutive days after admission with no need for renal replacement therapy and creatinine levels consistently below ×1.5 the level before admission. We adjusted models for age, gender, vasopressor treatment, mechanical ventilation and levels of creatinine, procalcitonin, platelets, and bilirubin at admission.

RESULTS: Of a total 213 with AKI at admission, 99 recovered prior kidney function during follow-up. Endothelial damage on admission, measured by Soluble Thrombomodulin (sTM), was the strongest predictor of a reduced chance of recovery of prior kidney function (sTM in the highest vs. three lower quartiles hazard ratio 0.39; 95% confidence interval 0.21-0.73, P = 0.003). In contrast, the degree of the initial inflammatory insult on the kidney, measured by neutrophil gelatinase-associated lipocalin (NGAL), failed to predict this outcome (NGAL in highest vs. three lower quartiles hazard ratio = 1.20; 95% CI 0.72-2.00; P = 0.48). Procalcitonin, a specific marker of bacterial infection, was also associated with the rate of recovery (PCT in highest vs. three lower quartiles hazard ratio = 0.59; 95% CI 0.36-0.98; P = 0.04).

CONCLUSION: AKI patients with high levels of sTM had a reduced chance of recovering prior renal function. Our findings support disintegration of the endothelium as a critical point in the pathogenesis of AKI that is refractory to treatment.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Itenov TS, Jensen JU, Ostrowski SR, et al. Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. Shock. 2017. PMID: 28505627. doi:10.1097/SHK.0000000000000804

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。